Short answer
Peptides.Media does not use one score to imply that a peptide is safe, legal, effective, and high quality. A peptide can look plausible in one area and still have weak human evidence, regulatory problems, or product-quality risks.
Separate dimensions, not one hype score
The scorecard separates efficacy, safety, regulatory risk, and product-quality risk. A peptide can have a plausible mechanism while still having weak human evidence or serious regulatory concerns.
Why human evidence gets its own label
Mechanism, animal studies, and anecdotes are not interchangeable with controlled human outcomes. Human evidence should match the claim: wound healing, weight loss, cognition, route, and dose are not interchangeable.
Why risk scores can be high on plausible topics
Regulatory risk asks whether the product and claim are allowed. Product-quality risk asks whether the marketed product is what it says it is. Neither proves or disproves the biology.
Sources
- 1.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 2.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.